- Price
- $24.55
- Day
- +6.23%
- Mkt Cap
- $3.93B
- 52W Range
- $10.66 – $24.62
- Volume
- 2.92M
- Beta
- 2.09
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Read full article
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Read full article
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.
Read full article
Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering.
Read full article
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Read full article
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
Caxton Associates LLP trimmed its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 55.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,035 shares of the company's stock after selling 44,382 shares during the
Read full article
D.A. Davidson and CO. reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 70.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,750 shares of the company's stock after selling 60,300 shares during the
Read full article
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Amova Asset Management Americas Inc. lessened its stake in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 18.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,595,370 shares of the company's stock after selling 352,593 shares during the period. Amova Asset Management Americas
Read full article
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read full article